FI4218804T3 - Myostatiinin estäjien ja yhdistelmähoitojen käyttö - Google Patents

Myostatiinin estäjien ja yhdistelmähoitojen käyttö

Info

Publication number
FI4218804T3
FI4218804T3 FIEP23157280.1T FI23157280T FI4218804T3 FI 4218804 T3 FI4218804 T3 FI 4218804T3 FI 23157280 T FI23157280 T FI 23157280T FI 4218804 T3 FI4218804 T3 FI 4218804T3
Authority
FI
Finland
Prior art keywords
smn
myostatin
myostatin inhibitor
repair
repair agent
Prior art date
Application number
FIEP23157280.1T
Other languages
English (en)
Finnish (fi)
Inventor
Kimberly Long
Adriana Donovan
Yung Chyung
Michelle Straub
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59093642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4218804(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Application granted granted Critical
Publication of FI4218804T3 publication Critical patent/FI4218804T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
FIEP23157280.1T 2016-06-13 2017-06-13 Myostatiinin estäjien ja yhdistelmähoitojen käyttö FI4218804T3 (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662349596P 2016-06-13 2016-06-13
US201762470157P 2017-03-10 2017-03-10
US201762486934P 2017-04-18 2017-04-18
US201762511702P 2017-05-26 2017-05-26
US201762512254P 2017-05-30 2017-05-30

Publications (1)

Publication Number Publication Date
FI4218804T3 true FI4218804T3 (fi) 2026-03-11

Family

ID=59093642

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP23157280.1T FI4218804T3 (fi) 2016-06-13 2017-06-13 Myostatiinin estäjien ja yhdistelmähoitojen käyttö

Country Status (22)

Country Link
US (2) US10946036B2 (enExample)
EP (3) EP3368069B1 (enExample)
JP (5) JP6823167B2 (enExample)
KR (5) KR20230169484A (enExample)
AU (4) AU2017283546C1 (enExample)
CL (1) CL2018003588A1 (enExample)
CY (1) CY1123678T1 (enExample)
DK (2) DK4218804T3 (enExample)
ES (2) ES3067719T3 (enExample)
FI (1) FI4218804T3 (enExample)
HR (2) HRP20201764T1 (enExample)
HU (1) HUE051480T2 (enExample)
IL (3) IL326484A (enExample)
LT (2) LT3368069T (enExample)
MY (2) MY185614A (enExample)
PE (1) PE20190205A1 (enExample)
PL (1) PL4218804T3 (enExample)
PT (2) PT4218804T (enExample)
RS (2) RS61090B1 (enExample)
SI (2) SI4218804T1 (enExample)
SM (1) SMT202000598T1 (enExample)
WO (1) WO2017218592A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
TWI760396B (zh) * 2016-06-17 2022-04-11 日商中外製藥股份有限公司 抗肌抑素抗體及使用方法
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
HRP20230308T1 (hr) * 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
US11857599B2 (en) 2017-04-03 2024-01-02 Acceleron Pharma Inc. Compositions and methods for treating spinal muscular atrophy
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
WO2019170930A1 (es) * 2018-03-09 2019-09-12 Universitat De Lleida Tratamiento para la atrofia muscular espinal
CN112334157A (zh) * 2018-04-17 2021-02-05 应用干细胞有限公司 治疗脊髓肌萎缩症的组合物和方法
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR102913697B1 (ko) 2019-02-05 2026-01-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR102925385B1 (ko) 2019-02-06 2026-02-11 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP2022537266A (ja) * 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
JP7597744B2 (ja) * 2019-06-19 2024-12-10 エフ． ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
EP4232151B1 (en) 2020-10-26 2025-10-22 Scholar Rock, Inc. Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
DK4358995T3 (da) 2021-06-23 2026-02-02 Scholar Rock Inc Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
KR20240049857A (ko) * 2021-07-19 2024-04-17 악셀레론 파마 인코포레이티드 Actrii 단백질 및 이의 용도
EP4426306A1 (en) * 2021-10-06 2024-09-11 F. Hoffmann-La Roche AG Novel combined administration
LT4518970T (lt) * 2022-05-04 2026-04-27 Scholar Rock, Inc. Miostatino inhibitoriaus panaudojimas spinalinės raumenų atrofijos gydymui
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
AU2024347940A1 (en) 2023-09-29 2026-04-30 Peptidream Inc. Peptide
TW202617762A (zh) * 2024-07-04 2026-05-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合潛伏肌生長抑制素的抗原結合分子及其醫藥用途
WO2026147753A1 (en) 2024-12-30 2026-07-09 Scholar Rock, Inc. Therapies for muscular dystrophies
WO2026152042A1 (en) 2025-01-10 2026-07-16 Scholar Rock, Inc. A novel class of musk agonists and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
DE69534468T2 (de) 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US8455627B2 (en) 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
ATE364632T1 (de) 2001-10-05 2007-07-15 Affimed Therapeutics Ag Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
US20040131614A1 (en) 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
AU2003267246A1 (en) 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
WO2005066204A2 (en) 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
CA2558478A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1755648A2 (en) 2004-05-27 2007-02-28 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007061995A2 (en) 2005-11-21 2007-05-31 Novartis Ag Biomarkers for statin-induced myopathy or rhabdomyolysis
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
WO2008067480A2 (en) 2006-11-29 2008-06-05 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
JP2010519256A (ja) 2007-02-23 2010-06-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法
KR101531722B1 (ko) 2007-03-30 2015-06-25 메르크 파텐트 게엠베하 음성 광학 분산도를 갖는 복굴절층
EP2144614A1 (en) 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
AU2008260445A1 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
US8952130B2 (en) 2009-02-24 2015-02-10 The Salk Institute For Biological Studies Designer ligands of TGF-β superfamily
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
PH12013500315A1 (en) 2010-08-16 2013-04-29 Amgen Inc Antibodies that bind myostatin, compositions and methods
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
US20130178454A1 (en) 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
BR112015027336A2 (pt) * 2013-05-01 2017-09-26 Genzyme Corp composições e processos para tratamento de atrofia muscular espinhal
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
US10004814B2 (en) 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
WO2015195094A1 (en) 2014-06-17 2015-12-23 Ember Therapeutics, Inc. Anti-activin and nati-myostatin antibodies and methods of using the same
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
WO2016168613A1 (en) * 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

Also Published As

Publication number Publication date
KR20230169484A (ko) 2023-12-15
NZ789269A (en) 2026-01-30
AU2017283546A1 (en) 2018-12-20
US20190255093A1 (en) 2019-08-22
MY199499A (en) 2023-11-01
NZ789250A (en) 2026-01-30
LT3368069T (lt) 2020-12-10
SMT202000598T1 (it) 2021-01-05
CL2018003588A1 (es) 2019-03-01
EP3785728A2 (en) 2021-03-03
JP2021063107A (ja) 2021-04-22
PL4218804T3 (pl) 2026-05-25
LT4218804T (lt) 2026-03-25
DK3368069T3 (da) 2020-11-02
HRP20260160T1 (hr) 2026-03-27
AU2017283546C1 (en) 2020-11-19
JP6823167B2 (ja) 2021-01-27
JP2025183233A (ja) 2025-12-16
AU2020210134B2 (en) 2021-11-04
IL263510A (en) 2019-01-31
JP2023164920A (ja) 2023-11-14
ES3067719T3 (en) 2026-05-25
KR20190017933A (ko) 2019-02-20
AU2021261907A1 (en) 2021-12-02
IL326484A (en) 2026-04-01
HUE051480T2 (hu) 2021-03-01
IL301468A (en) 2023-05-01
RS61090B1 (sr) 2020-12-31
AU2024203412A1 (en) 2024-06-27
EP4218804A3 (en) 2023-09-13
US20210283166A1 (en) 2021-09-16
EP3368069B1 (en) 2020-08-05
RS67857B1 (sr) 2026-04-30
JP7161554B2 (ja) 2022-10-26
JP7344337B2 (ja) 2023-09-13
WO2017218592A1 (en) 2017-12-21
CY1123678T1 (el) 2022-03-24
AU2021261907B2 (en) 2024-06-06
EP4218804B1 (en) 2026-01-21
JP2019523295A (ja) 2019-08-22
EP3785728A3 (en) 2021-04-28
PT4218804T (pt) 2026-04-07
HRP20201764T1 (hr) 2020-12-25
DK4218804T3 (da) 2026-02-09
JP2022101593A (ja) 2022-07-06
KR20260028184A (ko) 2026-03-03
NZ748917A (en) 2024-04-26
EP3368069A1 (en) 2018-09-05
SI4218804T1 (sl) 2026-03-31
SI3368069T1 (sl) 2021-03-31
MY185614A (en) 2021-05-25
KR102271635B1 (ko) 2021-07-06
KR20230028813A (ko) 2023-03-02
NZ789268A (en) 2026-01-30
AU2020210134A1 (en) 2020-08-13
PE20190205A1 (es) 2019-02-07
PT3368069T (pt) 2020-11-11
ES2830440T3 (es) 2021-06-03
US10946036B2 (en) 2021-03-16
AU2017283546B2 (en) 2020-05-21
KR20210082548A (ko) 2021-07-05
EP4218804A2 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
PE20190443A1 (es) Moleculas de acido nucleico para la reduccion de arnm de papd5 o papd7 para tratar la infeccion por hepatitis b
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
BR112021024463A2 (pt) Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas
EA201890006A1 (ru) Применение экзосом для лечения болезни
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
EP3684397A4 (en) SYSTEMS, PROCEDURES AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
CY1116703T1 (el) ΧΡΗΣΗ sGC ΔΙΕΓΕΡΤΩΝ, sGC ΕΝΕΡΓΟΠΟΙΗΤΩΝ, MOΝΩΝ ΚΑΙ ΣΕ ΣΥΝΔΥΑΣΜΟ ME PDE5 ΑΝΑΣΤΟΛΕΙΣ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΗΣ ΣΥΣΤΗΜΙΚΗΣ ΣΚΛΗΡΥΝΣΗΣ (SSc)
MX2023009712A (es) Composiciones oligonucleotidicas y sus metodos.
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
BRPI0516408B8 (pt) derivados de estilbeno e seu uso para ligação e formação de imagem de placas de amilóide
BR112016002164A2 (pt) anticorpos de antiactivina a e usos dos mesmos
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
BR112016004415A2 (pt) método de tratamento de um paciente diagnosticado com um glioblastoma, uso de uma quantidade eficaz de um anticorpo anti-vegf, composição e kit
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
BRPI0619224A2 (pt) monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
PE20180452A1 (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
MX2012010244A (es) Composiciones y metodos de tratamiento para enfermedad de parkinson mediante transferencia del gen bndf-flag a traves del poliplex de neurotensina a neuronas dopaminergicas nigrales.
MX2014004766A (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
CO6630085A2 (es) Tratamiento de artritis reumatoide con combinacion de laquinimod y metotrexato